SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-22-220150
Filing Date
2022-08-15
Accepted
2022-08-12 19:32:52
Documents
1
Group Members
IPSEN BIOPHARMACEUTICALS, INC.IPSEN PHARMA SAS

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d373153dsc13da.htm SC 13D/A 88151
  Complete submission text file 0001193125-22-220150.txt   89699
Mailing Address 42, RUE DU DOCTEUR BLANCHE PARIS I0 75016
Business Address 42, RUE DU DOCTEUR BLANCHE PARIS I0 75016 011 33144961010
Ipsen, S.A. (Filed by) CIK: 0001370483 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Subject) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87481 | Film No.: 221161851
SIC: 2834 Pharmaceutical Preparations